Harmony Biosciences (HRMY) Stock Analysis
NASDAQHealthcareBiotechnology
Track HRMY in your portfolio for free · Portfolio tracker
What Harmony Biosciences does
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Key metrics
ETFs linked to HRMY
Broad-market and Healthcare sector ETFs an investor holding Harmony Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how HRMY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze HRMY in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Harmony Biosciences?
- Harmony Biosciences trades under the ticker HRMY on NASDAQ.
- Which exchange is HRMY listed on?
- HRMY is listed on NASDAQ.
- What sector does Harmony Biosciences operate in?
- Harmony Biosciences is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze HRMY in a portfolio?
- PortView shows HRMY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.